commissioner

Cathy Engelbert will retire as WNBA commissioner at the end of the year, ending a tenure of seven-plus years that saw both tremendous growth and some turmoil for the league.

“In 2019, I had the privilege of being appointed the league’s first commissioner and to lead a league with enormous potential yet untapped awareness and significant undervaluation,” Engelbert said in a statement released by the WNBA. “Over the years, it has been amazing to watch WNBA players thrive and lead the massive cultural surge around women’s sports.”

Engelbert, 61, told the Associated Press that she has been considering retirement for months and wasn’t pressured into making the decision by NBA or WNBA stakeholders. She added that she will help with finding the next commissioner and with the transition period that follows.

“We’ll run a real succession process in the remaining four months,” Engelbert told AP. “If we don’t find someone, I’ll stay on.”

During Engelbert’s tenure, the WNBA has experienced record TV ratings and robust attendance, with a lucrative media rights deal being finalized this year and plans in place for expansion to 18 teams by 2030. An influx of talented and popular young players — including Caitlin Clark, Angel Reese and Paige Bueckers — helped along those lines.

Engelbert also helped the league and its players’ union agree on a new collective bargaining agreement this spring, resulting in the first million-dollar salaries for WNBA players.

Still, the negotiations leading up to the CBA were strained at times. Other issues surrounding the league — including player safety, the eligibility of transgender players, and the inconsistency of on-court officials — have caused some to question Engelbert’s leadership ability.

“Cathy has presided over the WNBA through the most significant period of growth in the league’s 30-year history,” NBA commissioner Adam Silver said in the WNBA’s news release. “We are grateful for Cathy’s leadership and unwavering commitment to the advancement of women’s basketball.”

The Associated Press contributed to this report.

Aug. 19 (UPI) — President Donald Trump is expected to nominate Dr. Heidi Overton, a White House policy aide, to lead the Food and Drug Administration.

The decision was reported by the Washington Post, The New York Times and Politico, all citing anonymous sources. Overton is an aide at the White House’s Domestic Policy Council and will be tapped to be the next FDA commissioner, sources say.

Overton will replace Marty Makary, who left the position in May, and the Senate will have to confirm her to the position.

The FDA commissioner is one of the most powerful jobs in U.S. health care. The FDA oversees drugs, vaccines, tobacco products, the bulk of the food supply and more. The position has remained open longer than expected as some have turned it down over fears of administration interference, the Post reported.

The position has been run by acting FDA Commissioner Kyle Diamantas, a friend of Donald Trump Jr., and a former partner at the law firm Jones Day.

Overton is board-certified in public health and general preventive medicine and was a general surgery resident at Johns Hopkins Hospital in Baltimore, where she also earned a doctorate in clinical investigation. She worked at the America First Policy Institute, a conservative think tank. She has also written articles calling abortion “corrosive” to women. She called abortion pills “far more dangerous to women” and has called for more controls on the pills.

In September, Secretary of Health and Human Services Robert F. Kennedy Jr. said Overton and Calley Means worked on a Make America Healthy Again strategy report calling for more review of chemicals in food and an increase in oversight over pharmaceutical advertisements, The Times reported.

Makary left the position in May because he disagreed with the administration’s policy of allowing tobacco and e-cigarette companies to sell flavored vapes. The White House had been pressuring Makary to allow the vapes, but he disagreed, citing their appeal to teens and young adults.

The FDA approved mango and blueberry vapes just after Trump had lunch with tobacco executives, The Times reported.

While she is a doctor and has been present for many FDA announcements at the White House, she hasn’t run a large agency before. The FDA has thousands of employees and shapes food safety and pharmaceutical policies.